SEC Form 4 · accession 0000899243-15-006341
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Asaf Danziger
Officer — Chief Executive Officer · Director
Period of report
Oct 2, 2015
Accepted (ET)
Oct 5, 2015 · 6:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF1 | $22.00 | Oct 2, 2015 | A | 413,910 | A | — | Oct 2, 2025 | Ordinary Shares | 413,910 | 413,910 | D |
Explanation of responses
- F1Options to buy 413,910 ordinary shares were granted contingent upon the consummation of the registrant's initial public offering and will vest and become exercisable in equal installments on each of October 2, 2016, 2017, 2018 and 2019, subject to Mr. Danziger's continued employment through such dates.